<i>MGMT</i> promoter methylation and <i>IDH1</i> mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.Agnieszka Woźniak, Paul M. Clément, J. Menten et al.|Journal of Clinical Oncology|2010Cited by 1
Efficacy and toxicity in postoperative concomitant treatment with radiotherapy and dacarbazine-fotemustine in newly diagnosed glioblastoma multiformeEvelyn Van de Werf, Frank Van Calenbergh, Paul M. Clément et al.|Radiotherapy and Oncology|2006Cited by 0